剖析伪进展现象，剥开I-洋葱的多层皮
Peeling the I-Onion to Demystify Pseudoprogression.
发表日期：2023 Sep 11
作者：
Erica S Tsang, Lillian L Siu
来源：
CANCER CELL
摘要：
在《癌细胞》期刊的这篇论文中，Topp等人对六项临床试验中，使用了雷珠单抗治疗的799名患者的数据进行了分析，这些患者在RECIST 1.1标准下进展了疾病。虽然有8.9%-24.4%的患者表现出≥30%的目标病灶缩小，然而11%-18%的患者却有≥20%的目标病灶增大。在考虑治疗的持续至疾病进展时，必须谨慎权衡治疗的益处和身体及财务毒性。版权所有 © 2023 Elsevier Inc. 保留所有权利。
In this issue of Cancer Cell, Topp et al. analyze data from 799 patients treated with pembrolizumab beyond progression by RECIST 1.1 across six trials. Although 8.9%-24.4% of patients demonstrate a ≥30% reduction in target lesions, conversely 11%-18% of patients had a ≥20% increase. The benefits of treatment beyond progression must be carefully weighed against physical and financial toxicities.Copyright © 2023 Elsevier Inc. All rights reserved.